What is ATUM?
ATUM operates at the intersection of computational biology and molecular manufacturing, providing an end-to-end suite of tools that includes gene design, sequence optimization, and high-throughput synthesis. The company's core value proposition lies in its ability to transform biological activity through precise sequence engineering, effectively turning biology into a predictable, scalable discipline. By offering sophisticated expression vectors and cellular engineering platforms, ATUM enables its clients to accelerate research timelines and improve the efficacy of complex biological products. Its market position is defined by a commitment to the engineering discipline, serving as a foundational partner for organizations seeking to bridge the gap between theoretical research and commercial-scale production.
How much funding has ATUM raised?
ATUM has raised a total of $2M across 1 funding round:
Debt
$2M
Debt (2020): $2M with participation from PPP
Key Investors in ATUM
PPP
Public-Private Partnership
What's next for ATUM?
With the recent influx of capital, ATUM is well-positioned to scale its infrastructure and expand its proprietary technology stack. The strategic focus will likely shift toward enhancing the throughput of its synthesis platforms and deepening its integration within the global biopharmaceutical supply chain. As the industry moves toward more complex therapeutic modalities, ATUM's ability to provide reliable, optimized genetic sequences will be paramount. The company is expected to prioritize the development of next-generation protein engineering tools, ensuring that its clients maintain a competitive edge in an increasingly data-driven and automated biological landscape. This trajectory suggests a sustained commitment to operational excellence and technological leadership in the synthetic biology market.
See full ATUM company page
